New pill could help immune system fight rare sarcomas

NCT ID NCT07014137

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental oral drug called ABSK043 in about 20 people with rare sarcomas (intimal sarcoma, head/neck angiosarcoma, or EHE). The drug blocks PD-L1, which may help the immune system recognize and kill cancer cells. The main goal is to see if tumors shrink and to check safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABSK043 (an oral drug that blocks PD-L1 to help the immune system attack cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for rare sarcomas that are hard to treat.
What could go wrong: This is a small, early-phase trial with only 20 people, so results may not apply widely. The drug is experimental and may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIOID HEMANGIOENDOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angiosarcoma epithelioid hemangioendothelioma intimal sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

UHN- Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 1Z5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.